Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

803

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2017

Study Completion Date

December 31, 2018

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Capecitabine

Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles

DRUG

Adjuvant chemotherapy using PF (5-Fluorouracil )

Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles

DRUG

Induction chemotherapy using PF (5-Fluorouracil)

Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles

Trial Locations (7)

Unknown

Cancer Center, Sun Yat Sen University, Guangzhou

Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

All Listed Sponsors
collaborator

The Hong Kong Anti-Cancer Society

OTHER

collaborator

hong Kong Cancer Fund

UNKNOWN

lead

Hong Kong Nasopharyngeal Cancer Study Group Limited

OTHER

NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter